194 related articles for article (PubMed ID: 34803077)
1. Renin-Angiotensin-Aldosterone System Inhibitors Prevent the Onset of Oxaliplatin-Induced Peripheral Neuropathy: A Retrospective Multicenter Study and in Vitro Evaluation.
Uchida M; Ushio S; Niimura T; Takechi K; Kawazoe H; Hidaka N; Tanaka A; Araki H; Zamami Y; Ishizawa K; Kitamura Y; Sendou T; Kawasaki H; Namba H; Shibata K; Tanaka M; Takatori S
Biol Pharm Bull; 2022 Feb; 45(2):226-234. PubMed ID: 34803077
[TBL] [Abstract][Full Text] [Related]
2. Preventive Effects of Renin-angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy: A Retrospective Observational Study.
Uchida M; Kawazoe H; Takatori S; Namba H; Uozumi R; Tanaka A; Kawasaki H; Araki H
Clin Ther; 2018 Jul; 40(7):1214-1222.e1. PubMed ID: 29983264
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment.
Kang L; Tian Y; Xu S; Chen H
J Neurol; 2021 Sep; 268(9):3269-3282. PubMed ID: 32474658
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
[TBL] [Abstract][Full Text] [Related]
5. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S
Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347
[TBL] [Abstract][Full Text] [Related]
6. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
[TBL] [Abstract][Full Text] [Related]
7. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies.
Miyamoto T; Domoto R; Sekiguchi F; Kamaguchi R; Nishimura R; Matsuno M; Tsubota M; Fujitani M; Hatanaka S; Koizumi Y; Wang D; Nishibori M; Kawabata A
J Pharmacol Sci; 2022 Mar; 148(3):315-325. PubMed ID: 35177211
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro.
Shigematsu N; Kawashiri T; Kobayashi D; Shimizu S; Mine K; Hiromoto S; Uchida M; Egashira N; Shimazoe T
Sci Rep; 2020 Apr; 10(1):6734. PubMed ID: 32317735
[TBL] [Abstract][Full Text] [Related]
9. Paeoniflorin ameliorates oxaliplatin-induced peripheral neuropathy via inhibiting neuroinflammation through influence on gut microbiota.
Xu J; Lu L; Jiang S; Qin Z; Huang J; Huang M; Jin J
Eur J Pharmacol; 2024 May; 971():176516. PubMed ID: 38513881
[TBL] [Abstract][Full Text] [Related]
10. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L
BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227
[TBL] [Abstract][Full Text] [Related]
11. Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy.
Chen SJ; Chen LH; Yeh YM; Lin CK; Lin PC; Huang HW; Shen MR; Lin BW; Lee JC; Lee CC; Lee YF; Chiang HC; Chang JY
Theranostics; 2021; 11(10):4672-4687. PubMed ID: 33754020
[No Abstract] [Full Text] [Related]
12. A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system.
Coolbrandt A; Tobback H; Govaerts R; Vandezande L; Vinckx M; Laenen A; Wildiers H; Verslype C; Dekervel J; Van Herpe F; Van Cutsem E
ESMO Open; 2023 Apr; 8(2):101205. PubMed ID: 37018872
[TBL] [Abstract][Full Text] [Related]
13. "Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.
Ishiguro K; Hayashi K; Sasamura H; Sakamaki Y; Itoh H
Hypertension; 2009 Jan; 53(1):83-9. PubMed ID: 19047581
[TBL] [Abstract][Full Text] [Related]
14. Mitotherapy prevents peripheral neuropathy induced by oxaliplatin in mice.
Maia JRLCB; Machado LKA; Fernandes GG; Vitorino LC; Antônio LS; Araújo SMB; Colodeti LC; Fontes-Dantas FL; Zeidler JD; Saraiva GN; Da Poian AT; Figueiredo CP; Passos GF; da Costa R
Neuropharmacology; 2024 Mar; 245():109828. PubMed ID: 38158014
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral Neuropathy.
Warren G; Osborn M; Tsantoulas C; David-Pereira A; Cohn D; Duffy P; Ruston L; Johnson C; Bradshaw H; Kaczocha M; Ojima I; Yates A; O'Sullivan SE
J Pain; 2024 Jul; 25(7):104470. PubMed ID: 38232863
[TBL] [Abstract][Full Text] [Related]
17. Antioxidants Improve Oxaliplatin-Induced Peripheral Neuropathy in Tumor-Bearing Mice Model: Role of Spinal Cord Oxidative Stress and Inflammation.
Agnes JP; Santos VWD; das Neves RN; Gonçalves RM; Delgobo M; Girardi CS; Lückemeyer DD; Ferreira MA; Macedo-Júnior SJ; Lopes SC; Spiller F; Gelain DP; Moreira JCF; Prediger RD; Ferreira J; Zanotto-Filho A
J Pain; 2021 Aug; 22(8):996-1013. PubMed ID: 33774154
[TBL] [Abstract][Full Text] [Related]
18. Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin.
Yildirim N; Cengiz M
Support Care Cancer; 2020 Oct; 28(10):4781-4788. PubMed ID: 31974772
[TBL] [Abstract][Full Text] [Related]
19. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
